Navigation Links
Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21
Date:1/24/2011

74; (Epoetin alfa) and ENBREL recalls.  These increases were partially offset by lower excess capacity charges and lower royalties, primarily for ENBREL.Research & Development (R&D) expenses decreased 5 percent to $825 million in the fourth quarter of 2010 versus $864 million in the fourth quarter of 2009.  This decrease was driven primarily by the $60 million licensing fee payment in the fourth quarter of 2009 associated with the Array BioPharma agreement.  This decrease in licensing fees was partially offset by lower cost recoveries associated with ongoing collaborations and higher staff related costs in 2010.For the year, R&D expenses were $2,773 million in 2010 versus $2,739 million in 2009, an increase of 1 percent.  The increase was driven primarily by lower cost recoveries associated with ongoing collaborations and higher staff related costs in 2010.  This was largely offset by lower licensing fees, principally associated with payments made in 2009 under the Cytokinetics and Array BioPharma agreements, and reduced denosumab clinical trial expenses in 2010.Selling, General & Administrative (SG&A) expenses declined slightly to $1,142 million in the fourth quarter of 2010 versus $1,159 million in the fourth quarter of 2009.For 2010, SG&A expenses increased 5 percent to $3,925 million versus $3,737 million in 2009.  This increase was due primarily to higher staff related costs, higher promotional costs for Prolia and other marketed products, and higher litigation expenses.ENBREL profit share expenses were $319 million and $1,184 million and $308 million and $1,163 million for the three and twelve months ended Dec. 31, 2010 and 2009, respectively.The adjusted tax rate for the fourth quarter of 2010 was 15.5 percent compared to 15.9 percent for the fourth quarter of 2009.  The decrease was due primarily to the full year benefit of the federal R&D credit recognized in the fourth quarter of
'/>"/>
SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year
2. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. PLC Systems Reports Fourth Quarter 2007 Results
5. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
6. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
7. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
8. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
9. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
10. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
11. Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , Jan. 15, ... new market research report is available ... Global Markets and Technologies for ... on Routes of Administration ...
(Date:1/15/2014)... 2014  A novel wearable injector slightly larger than an Oreo ... to self-inject prescription drugs in the large doses required to ... autoimmune deficiencies, and genetic disorders.  An emerging ... 2018, according to analysts.   Many of these drugs will require ...
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... report results for the fourth quarter of 2013 on Monday, ... scheduled for release after the close of trading. ... a conference call to discuss the operating highlights and financial ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... Inc. (NASDAQ: QCOR ) today announced ... to its Board of Directors.  Dr. Whitcup is ... Chief Scientific Officer at Allergan, Inc.  In that ... research and development organization, including medical affairs, drug ...
... Feb. 16, 2012 OPKO Health, Inc. and ChromaDex ... a strategic alliance pursuant to which ChromaDex has licensed ... health care technologies for distribution and business development throughout ... commercialized are BluScience™ ( www.bluscience.com ), ChromaDex,s ...
Cached Medicine Technology:Questcor Pharmaceuticals Appoints Scott M. Whitcup, M.D., to Board of Directors 2Questcor Pharmaceuticals Appoints Scott M. Whitcup, M.D., to Board of Directors 3Questcor Pharmaceuticals Appoints Scott M. Whitcup, M.D., to Board of Directors 4OPKO Health, Inc. Invests in ChromaDex® Corp. 2OPKO Health, Inc. Invests in ChromaDex® Corp. 3OPKO Health, Inc. Invests in ChromaDex® Corp. 4OPKO Health, Inc. Invests in ChromaDex® Corp. 5
(Date:4/17/2014)... PLOS Pathogens , children who live in regions ... an immune response to infection with malaria parasites that ... fever and illness and partially control the growth of ... researchers develop future interventions that prevent or mitigate the ... approximately 200 million cases of malaria occur worldwide, resulting ...
(Date:4/17/2014)... the April issue of Immunity , Kevin J. ... Research, says it,s time to take a fresh look ... sepsis, which kills millions worldwide every year, including more ... into the bloodstream to fight an injury or infection ... maintaining good health without inflammation, wounds and infections ...
(Date:4/17/2014)... 2014) Doctors who treat patients with a ... can face an agonizing treatment decision. , The ... and help relieve shortness of breath. But some ... can cause potentially fatal complications following transplantation. , ... Dilling, medical director of Loyola University Medical Center,s ...
(Date:4/17/2014)... Irvine, Calif., April 17, 2014 By discovering a ... immediately after a stroke, researchers at UC Irvine and ... therapies that may limit or prevent stroke-induced brain damage. ... the fourth-leading cause of death and primary reason for ... damaged in a stroke and lets blood-borne material into ...
(Date:4/17/2014)... to ward off depression among retirees, particularly among those ... The Journals of Gerontology, Series B: Psychological ... " Internet Use and Depression Among Retired Older Adults ... authors report that Internet use reduced the probability of ... sample. , Late-life depression affects between 5 and ...
Breaking Medicine News(10 mins):Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Internet use may cut retirees' depression 2
... (Nasdaq: DIET ), a leading provider of convenient ... for the third,quarter and nine months ended September 30, ... were $4.8 million, compared to,$6.8 million in the prior ... or $(0.13) per diluted share, for the third quarter ...
... of successful pregnancy, research suggests , , THURSDAY, Nov. 13 ... to harden plastic packaging for many foods and beverages, ... (BPA) could hurt the chances of successful in vitro ... the uterus, according to presentations at the American Society ...
... 13 Debiopharm Group,(Debiopharm), a global independent ... and particularly oncology, today,announced that the New ... formulation,of Trelstar(R) (triptorelin pamoate) has been accepted ... and Drug Administration (FDA). Trelstar(R) is a,luteinizing ...
... Alaska,s alcohol tax increases tied to a drop in cirrhosis, ... Raising state taxes on alcohol may trigger an immediate drop ... new research reveals. , The finding is based on the ... to raise taxes on beer, wine and liquor in 1983 ...
... g has been approved by the U.S. Food and Drug Administration ... dosing regimen to treat moderate to severe postmenopausal dyspareunia (painful sexual ... , ... COLLEGEVILLE, Pa. (Business Wire EON) November 13, 2008 ...
... The American Veterinary,Medical Association (AVMA) hand delivered ... Barack Obama, congratulating him on his historic,election to ... and,animal-related issues on which the AVMA is prepared ... to President-elect Obama, signed by AVMA Chief Executive,Officer ...
Cached Medicine News:Health News:eDiets.com(R) Announces Q3 2008 Results 2Health News:eDiets.com(R) Announces Q3 2008 Results 3Health News:eDiets.com(R) Announces Q3 2008 Results 4Health News:eDiets.com(R) Announces Q3 2008 Results 5Health News:eDiets.com(R) Announces Q3 2008 Results 6Health News:eDiets.com(R) Announces Q3 2008 Results 7Health News:Chemical in Plastics May Cause Fertility Problems 2Health News:Chemical in Plastics May Cause Fertility Problems 3Health News:Debiopharm Announces U.S. NDA Filing of Trelstar(R) 6-Month Formulation for Locally Advanced or Metastatic Prostate Cancer 2Health News:Booze Taxes Lower Alcohol-Linked Deaths 2Health News:Booze Taxes Lower Alcohol-Linked Deaths 3Health News: FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia – Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause 2Health News: FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia – Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause 3Health News: FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia – Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause 4Health News:AVMA Congratulates President-Elect Obama, Highlights Key Issues 2
... can code the charge while completing a chart ... away from office, both directly feeding the charge ... Encounter Form/Superbill, data entry can be done with ... payments are posted by reflecting open item charges, ...
The HearTwave system is the original stand-alone Microvolt T-Wave Alternans (MTWA) testing platform....
... that a second mirror adds, then you may ... features the same 1.5x magnification as the G-1 ... and 64 respectively. Available in standard (flange) or ... "Flanged" model for laser use. Provides ...
... The AFX (Air Fluid ... image lens designed for use ... addition to its use as ... lens, the low profile and ...
Medicine Products: